Padeliporfin, sold under the brand name Tookad, is a medication used to treat men with prostate cancer. The most common side effects include problems with urinating (pain, inability to pass urine, strong urge to pass urine, frequent urination, and incontinence), sexual problems (erectile dysfunction and ejaculation failure), blood in urine, urinary tract infection, and pain and bleeding around the genital area. Padeliporfin was approved for medical use in the European Union in November 2017. The active ingredient in Tookad is padeliporfin di-potassium.
Property | Value |
---|---|
dbo:abstract |
|
dbo:alternativeName |
|
dbo:casNumber |
|
dbo:drugbank |
|
dbo:fdaUniiCode |
|
dbo:kegg |
|
dbo:pubchem |
|
dbo:thumbnail | |
dbo:wikiPageExternalLink | |
dbo:wikiPageID |
|
dbo:wikiPageLength |
|
dbo:wikiPageRevisionID |
|
dbo:wikiPageWikiLink | |
dbp:atcPrefix |
|
dbp:atcSuffix |
|
dbp:c |
|
dbp:casNumber |
|
dbp:drugbank |
|
dbp:h |
|
dbp:iupacName |
|
dbp:kegg |
|
dbp:legalEu |
|
dbp:legalStatus |
|
dbp:legalUk |
|
dbp:licenceEu |
|
dbp:n |
|
dbp:o |
|
dbp:pd |
|
dbp:pubchem |
|
dbp:s |
|
dbp:smiles |
|
dbp:stdinchi |
|
dbp:stdinchikey |
|
dbp:synonyms |
|
dbp:tradename |
|
dbp:unii |
|
dbp:wikiPageUsesTemplate | |
dcterms:subject | |
rdf:type | |
rdfs:comment |
|
rdfs:label |
|
owl:sameAs | |
prov:wasDerivedFrom | |
foaf:depiction | |
foaf:isPrimaryTopicOf | |
is dbo:wikiPageRedirects of | |
is dbo:wikiPageWikiLink of | |
is foaf:primaryTopic of |